Evaluation of some radioprotectors by the survival study of rats exposed to lethal dose of whole body gamma radiation.

Basu, S.; Srinivasan, M. N.; Chuttani, Krishna; Ghose, Arup K.

doi:10.1269/jrr.26.395

Cited by 7 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prophylactic treatment with Actovegin on 6 consecutive days before the radiation did not reveal any preventive effect of Actovegin. In a similar study, Basu et al [33] examined the radioprotective effects of Actovegin in adult rats; while control animals died within 30 days, the rats treated with Actovegin 1 hour before irradiation had a statistically significant higher survival rate, as already described in the study of Bauer and Locker [31], thereby confirming their results. By contrast, Tamou and Trott [34] describe findings on the occurrence of radiation-induced ulcers in the rectum of rats where the results in the Actovegin group did not differ from control conditions.…”

Section: Wound Healing and Effects On Radiation-induced Damagesupporting

confidence: 55%

Actovegin®: a biological drug for more than 5 decades

Buchmayer

Pleiner

Elmlinger³

et al. 2011

Wien Med Wochenschr

View full text Add to dashboard Cite

Actovegin(®) is a biological drug manufactured from a natural source: it is a calf blood hemodialysate. Its therapeutic benefits stem from a variety of pharmacodynamic actions that can be summarized to a common goal, i.e. the enhancement of cellular metabolism; this results from an insulin-like activity mediated by Inositol-phospho-oligosaccharides. Actovegin(®) results in beneficial effects in several pathophysiological clinical settings including malfunction of the blood circulation and trophic disturbances in the brain, impairment of peripheral blood circulation and associated diseases, dermal transplants and acute and chronic wounds. Here, we give an overview of the pharmacodynamic actions of calf-blood hemidialysate and its beneficial effects in a variety of clinical settings.

show abstract

Section: Wound Healing and Effects On Radiation-induced Damagesupporting

confidence: 55%

Actovegin®: a biological drug for more than 5 decades

Buchmayer

Pleiner

Elmlinger³

et al. 2011

Wien Med Wochenschr

View full text Add to dashboard Cite

show abstract

“…Actovegin also has beneficial, regenerative effects in the treatment of radiation-induced damage [8], as well as in disturbances of blood circulation [9,10]. However, most recently, its neuroprotective effects on related distinct pathophysiological cellular pathways have been examined closely.…”

Section: In Vitro and In Vivo Effects Of Actoveginmentioning

confidence: 99%

Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action

Machicao¹,

Mureșanu²,

Hundsberger³

et al. 2012

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…It is mentioned that the transferability of in vitro results to the human physiological situation is limited but it is to note that this study has also a new direct relation to inflammations in sports medicine. Actovegin® is not only used in the above mentioned scopes of application and in skeletal muscle, but also as anti-inflammatory medication in skeletal muscle and in tendinopathies, e.g., on the patellar and achilles tendon (Reichl et al 2017;Boiarinov et al 1998;Derev'yannykh et al 2008;Appiah 2002;Biland et al 1985;Buchmayer et al 2011;Somogyi et al 1979;Chanh et al 1980;Lanner and Argyropoulos 1975;Mochida et al 1989;Neinhardt 1967;Schonwald et al 1991;Basu et al 1985;Bauer and Locker 1974;Beetz et al 1996;Spessotto et al 1993). Actovegin® is used as peritendinous injection (not intra-tendinous).…”

Section: Ad 2 (Differential Effect After Lps Vs Pma Stimulation)mentioning

confidence: 99%

“…(e.g., angiopathy and ulcus cruris) (Buchmayer et al 2011;Chanh et al 1980;Lanner and Argyropoulos 1975), wound healing issues (e.g., torpid wounds, decubitus) (Buchmayer et al 2011;Mochida et al 1989;Neinhardt 1967;Schonwald et al 1991) and mucosal lesions after radiation (Basu et al 1985;Bauer and Locker 1974;Beetz et al 1996;Buchmayer et al 2011;Spessotto et al 1993).…”

Section: Introductionmentioning

confidence: 99%

Actovegin® reduces PMA-induced inflammation on human cells

et al. 2020

View full text Add to dashboard Cite

Purpose The effect of Actovegin® was investigated on PMA- and LPS-induced human peripheral blood mononuclear cells (PBMCs). Methods PBMCs (1 × 106 cells/ml) from five blood donors (2 f, 3 m; 45–55 years) were grown in medium and exposed to Actovegin® in the presence or absence of PMA or LPS. Supernatants were collected to assess the concentration of cytokines (TNF-α, IL-1beta, IL-6 and IL-10). The reactive oxygen species (ROS) were assessed by a ROS-GloTM H2O2 assay. Results Stimulation of cells by PMA or LPS (without Actovegin®) significantly increased the secretion of IL-1beta, IL-6, IL-10 and TNF-α from PBMCs, compared to controls. Pre-treatment of cells with Actovegin® (1, 5, 25, 125 µg/ml) plus PMA significantly decreased the secretion of IL-1beta from PBMCs, compared to controls (PMA without Actovegin®). In contrast, addition of Actovegin® (1, 5, 25, 125 and 250 µg/ml) plus LPS did not alter the IL-1beta production, compared to controls (LPS without Actovegin®). TNF-α, IL-6 and IL-10 do not contribute to the reduction of inflammatory reactions with Actovegin®. Conclusions Actovegin® can reduce the PMA-induced IL-1beta release and the ROS production from PBMCs. These findings may help to explain the clinically known positive effects of Actovegin® on athletic injuries with inflammatory responses (e.g., muscle injuries, tendinopathies).

show abstract

Evaluation of some radioprotectors by the survival study of rats exposed to lethal dose of whole body gamma radiation.

Cited by 7 publications

References 4 publications

Actovegin®: a biological drug for more than 5 decades

Actovegin®: a biological drug for more than 5 decades

Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action

Actovegin® reduces PMA-induced inflammation on human cells

Contact Info

Product

Resources

About